Fact Sheet

Fact Sheet: July 10, 2017

Developer of the Portable Neuromodulation Stimulator (PoNS ) Therapy

Helius Medical Technologies is a Newtown, PA-based medical device company developing and commercializing the PoNS

Therapy platform, a powerful wearable direct current stimulation technology to treat movement and gait disorders in patients with traumatic brain injury (TBI) and chronic neurological disease. The first targeted application of the PoNS is for

balance disorder tied to mild to moderate TBI. The US neurostimulation device market is forecast to grow to $4 billion in 2018.

PoNS Therapy platform:

Helius is led by an experienced

management team. CEO Phil Deschamps, CFO & COO Joyce LaViscount and CMO Jonathan Sackier each bring over 30+ years of experience in Health Sciences industry with a focus on development and commercialization of healthcare products.

The company is nearing completion of a 120 patient double-blind, randomized, sham -controlled study of the safety and effectiveness of the PoNS device for

cranial nerve noninvasive neuromodulation in subjects with a chronic balance deficit due to mild to moderate TBI. The Company plans to submit for FDA, Health Canada and CE Mark approval and TGA regulatory approval of the PoNS device in 2H 2017.

In addition to over $7 million in grants raised by the inventors, the Company has raised over $40 million in equity capital since June 2014, and has

received $1.8 million in funding from the U.S. Army in support of PoNS clinical development, with a further $1 million expected later in 2017.

The Company filed a registration statement on Form S-3 in January 2017

establishing a $100 million shelf; $9.5 million was taken down in the February 2017 registered offering. Helius also completed a private placement financing in June 2017, raising an additional $5.275 million.

Helius shares are currently traded on the Toronto Stock Exchange (symbol: HSM) &

Over-The-Counter Bulletin Board in the U.S. (symbol: HSDT) with a goal to be listed on a US national securities exchange.

The Company has received ISO 13485 Certification, which permits submission to Health Canada, CE Mark in Europe and TGA in Australia.

Helius Medical s PoNS Therapy

The PoNS device delivers specially-patterned electrical stimulation developed to mirror nerve impulses to the brain through

143-gold-plated electrodes on the mouthpiece which is placed on the tongue;

Stimulation of the brain and

brain-stem via cranial nerve innervation of the tongue is hypothesized to encourage neuroplasticity, or a re-routing , enabling the damaged brain to compensate for lost function due to trauma or

disease, by recruiting existing working neurons;

The PoNS device, when used in combination with specialized physical or cognitive therapy, has been shown

to improve symptoms of patients with chronic neurological symptoms caused by disease or trauma;

Relative to most neurological drug and device treatments,

shorter clinical timelines, fewer study subjects and a shortened regulatory pathway offer relatively lower-cost opportunities to bring new indications to market;

Key near-term focus is the ongoing FDA registrational trial for PoNS Therapy for the treatment of balance deficit associated with mild to moderate TBI.

Investment Highlights for Helius Medical Technologies

One of the few pure-play medical device company in the large and growing neuromodulation market. The neuromodulation market is estimated at nearly

$6 billion worldwide by 2020 and is expected to grow in the double digits on a percentage basis annually. Significant industry consolidation by large, diversified medical device companies has left few pure-play companies developing and

commercializing novel therapies. Differentiated technologies like the PoNS device capture market share relatively quickly post-launch.

has a number of compelling milestones. The company has a goal to have its shares listed on a US national securities exchange, a critical component in potentially broadening the US institutional investor base. Data from the 120 patient

double-blind, randomized, sham-controlled trial in TBI is expected to read out in early 2H2017. Assuming FDA clearance, the 510(k)-de Novo to Class II device classification could allow for commercial

launch as early as 1H2018.

PoNS Therapy could play a unique role in the treatment paradigm for multiple neurological deficits. The unique and non-invasive neuromodulation approach, in conjunction with physical or cognitive therapy, as well as pharmacotherapies, could allow for potential broad applicability across a range of indications beyond TBI.

Positive outcomes with PoNS Therapy could reduce the cost of pharmaceutical and rehabilitation treatments for patients that are incurred with today s care plans.

Flexible business model. If the PoNS Therapy is approved for commercialization, the combination of the wearable pulse generator and disposable

mouthpiece could result in a recurring revenue stream. The service model is expected to launch in a clinic setting initially, with potential expansion to a home-based therapy care plan support model, with existing reimbursement for treatment. The de

Novo device classification affords for relatively short clinical trials with a small number of subjects, translating to relatively low cost development to expand into additional indications.

Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks are discussed

more fully in the Risk Factors section of our Transition Report on Form 10-K for the period ended December 31, 2016, which we filed with the SEC on April 3, 2017. These risks include the

Forward-Looking Statements

This fact sheet contains

forward-looking statements and forward-looking information as such terms are defined under applicable U.S. federal securities and Canadian securities legislation. All statements other than statements of historical fact contained in this fact sheet

constitute forward-looking statements and forward-looking information, including, without limitation, statements containing the words believe , may , plan , should , predict ,

potential , will , estimate , continue , anticipate , intend , expect , seek , mission , goal and similar words, variations, expressions

or the negative thereof. Forward-looking statements are necessarily based on estimates and assumptions made by management of the Helius Medical Technologies, Inc. ( Helius , we or the Company ) in light of experience

and perception of historical trends, current conditions and expected future developments, as well as the factors management of the Company believes are appropriate. Forward-looking statements and information in this fact sheet include but are not

limited to statements relating to:

statements reflect management of the Company s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the

Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future

results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others, those risks described in Risk Factors above and the risks described in our SEC filings, including our

Transition Report on Form 10-K for the period ended December 31, 2016 and our other SEC filings from time to time.

This fact sheet speaks as of its date and we, our advisors, and our and their affiliates and representatives undertake no obligation to update, revise or

correct the information contained herein, except as required by law.

Industry and Market Data

This fact sheet contains industry and market data that we obtained from independent industry publications. We have not independently confirmed this data and,

although we believe it is generally reliable, it involves a number of assumptions and limitations, it is inherently imprecise, and you are cautioned not to place undue reliance on it.